Arcutis Biotherapeutics Inc [ARQT] Revenue clocked in at $3.69 million, down -86.76% YTD: What’s Next?

Arcutis Biotherapeutics Inc [NASDAQ: ARQT] plunged by -$0.07 during the normal trading session on Monday and reaching a high of $2.11 during the day while it closed the day at $1.96. The company report on November 3, 2023 at 7:30 AM that Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update.

Achieved total revenues of $38.1 million in the third quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream 0.3% were $8.1 million, a 70% increase compared to the second quarter of 2023, driven by sequential improvement in gross-to-net (GTN) down to the low 70 percent range, as well as continued demand growth.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Received U.S. Food and Drug Administration (FDA) approval for the expanded indication of ZORYVE in plaque psoriasis down to the age of 6.

Arcutis Biotherapeutics Inc stock has also loss -3.92% of its value over the past 7 days. However, ARQT stock has declined by -75.56% in the 3 months of the year. Over the past six months meanwhile, it has lost -76.67% and lost -86.76% year-on date.

The market cap for ARQT stock reached $184.98 million, with 94.38 million shares outstanding and 77.27 million shares in the current float. Compared to the average trading volume of 2.22M shares, ARQT reached a trading volume of 5998335 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Arcutis Biotherapeutics Inc [ARQT]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ARQT shares is $15.86 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ARQT stock is a recommendation set at 1.86. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Mizuho have made an estimate for Arcutis Biotherapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on October 26, 2023.

The Average True Range (ATR) for Arcutis Biotherapeutics Inc is set at 0.30, with the Price to Sales ratio for ARQT stock in the period of the last 12 months amounting to 50.13. The Price to Book ratio for the last quarter was 2.60, with the Price to Cash per share for the same quarter was set at 2.42.

ARQT stock trade performance evaluation

Arcutis Biotherapeutics Inc [ARQT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.92. With this latest performance, ARQT shares dropped by -17.30% in over the last four-week period, additionally sinking by -76.67% over the last 6 months – not to mention a drop of -88.95% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ARQT stock in for the last two-week period is set at 32.24, with the RSI for the last a single of trading hit 37.54, and the three-weeks RSI is set at 30.10 for Arcutis Biotherapeutics Inc [ARQT]. The present Moving Average for the last 50 days of trading for this stock 3.47, while it was recorded at 1.97 for the last single week of trading, and 9.08 for the last 200 days.

Arcutis Biotherapeutics Inc [ARQT]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Arcutis Biotherapeutics Inc [ARQT] shares currently have an operating margin of -8183.04 and a Gross Margin at +54.02. Arcutis Biotherapeutics Inc’s Net Margin is presently recorded at -8449.76.

Return on Total Capital for ARQT is now -76.62, given the latest momentum, and Return on Invested Capital for the company is -79.22. Return on Equity for this stock declined to -122.80, with Return on Assets sitting at -72.65. When it comes to the capital structure of this company, Arcutis Biotherapeutics Inc [ARQT] has a Total Debt to Total Equity ratio set at 96.64. Additionally, ARQT Total Debt to Total Capital is recorded at 49.15, with Total Debt to Total Assets ending up at 45.08. Long-Term Debt to Equity for the company is recorded at 96.33, with the Long-Term Debt to Total Capital now at 48.99.

Reflecting on the efficiency of the workforce at the company, Arcutis Biotherapeutics Inc [ARQT] managed to generate an average of -$1,162,157 per employee. Receivables Turnover for the company is 0.84 with a Total Asset Turnover recorded at a value of 0.01.Arcutis Biotherapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.39 and a Current Ratio set at 6.72.

Earnings per share (EPS) analysis for Arcutis Biotherapeutics Inc [ARQT] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ARQT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Arcutis Biotherapeutics Inc go to 9.80%.

Arcutis Biotherapeutics Inc [ARQT]: Institutional Ownership

The top three institutional holders of ARQT stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in ARQT stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in ARQT stock with ownership which is approximately 5.7994%.